title: Randomised trial to compare a protective effect of Clopidogrel Versus TIcagrelor on coronary Microvascular injury in ST-segment Elevation myocardial infarction (CV-TIME trial).
abstract: OBJECTIVE
  Ticagrelor has shown greater, more rapid and more consistent platelet inhibition than clopidogrel. However, the superiority of ticagrelor for preventing ischaemic damage in STEMI patients has not been proven. The aim of this trial was to assess whether ticagrelor is superior to clopidogrel in preventing microvascular injury in ST-elevation myocardial infarction (STEMI).
  
  
  RESULTS
  Patients with STEMI underwent prospective random assignment to receive a loading dose (LD) of clopidogrel 600 mg or ticagrelor 180 mg (1:1 ratio) before primary percutaneous coronary intervention (PCI). As the primary endpoint, the index of microcirculatory resistance (IMR) was measured immediately after primary PCI. The secondary endpoint was the infarct size estimated from the wall motion score index (WMSI). A total of 76 patients were enrolled (clopidogrel group=38, ticagrelor group=38). The IMR in the ticagrelor group was significantly lower than that in the clopidogrel group (22.2±18.0 vs. 34.4±18.8 U, p=0.005). Cardiac enzymes were less elevated in the ticagrelor group than in the clopidogrel group (CK peak; 2,651±1,710 vs. 3,139±2,698 ng/ml, p=0.06). Infarct size, estimated by WMSI, was not different between the ticagrelor and clopidogrel groups at baseline (1.55±0.30 vs. 1.61±0.29, p=0.41) or after three months (1.42±0.33 vs. 1.47±0.33, p=0.57).
  
  
  CONCLUSIONS
  In patients with STEMI treated by primary PCI, a 180 mg LD of ticagrelor might be more effective in reducing microvascular injury than a 600 mg LD of clopidogrel, as demonstrated by IMR immediately after primary PCI.
authors.affiliation: Department of Internal Medicine, Inha University Hospital, Incheon, South Korea.
authors.forename: Sang-Don
authors.initials: SD
authors.lastname: Park
authors.forename: Man-Jong
authors.initials: MJ
authors.lastname: Lee
authors.forename: Yong-Soo
authors.initials: YS
authors.lastname: Baek
authors.forename: Sung-Woo
authors.initials: SW
authors.lastname: Kwon
authors.forename: Sung-Hee
authors.initials: SH
authors.lastname: Shin
authors.forename: Seong-Ill
authors.initials: SI
authors.lastname: Woo
authors.forename: Dae-Hyeok
authors.initials: DH
authors.lastname: Kim
authors.forename: Jun
authors.initials: J
authors.lastname: Kwan
authors.forename: Keum-Soo
authors.initials: KS
authors.lastname: Park
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000368:Aged; D000077144:Clopidogrel; D003402:Creatine Kinase / Q000097:blood; D004452:Echocardiography; D005260:Female; D006801:Humans; D008297:Male; D055806:Microvessels / Q000503:physiopathology*; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D000072657:ST Elevation Myocardial Infarction / Q000097:blood / Q000000981:diagnostic imaging / Q000628:therapy*; D012720:Severity of Illness Index; D000077486:Ticagrelor; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014655:Vascular Resistance / Q000502:physiology
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D003402:Creatine Kinase; D000077486:Ticagrelor; D000241:Adenosine; D013988:Ticlopidine